Eagleman, if you track through the last years presentations and other announcements youll soon see the history and what's likely to roll this year.
Today appears to be the second leg up this year and takes the total 2018 re rate to close to 300% following a year with devistating news for cohort 29 on Breast cancer trials. None of us will forget her. But the PTX trials process has been re commenced without fault and we are now seeing the MC start to reflect the potential which yes does raise big pharma interest (it is hoped). [email protected] for more.
PTX Price at posting:
14.0¢ Sentiment: Hold Disclosure: Held
